KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone857-999-0075
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.13 million
Profitability
Miscellaneous
Employees33
Next Earnings Date9/13/2019 (Estimated)
OptionableNot Optionable
Kalvista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions
What is Kalvista Pharmaceuticals' stock symbol?
Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."
How were Kalvista Pharmaceuticals' earnings last quarter?
Kalvista Pharmaceuticals Inc (NASDAQ:KALV) issued its earnings results on Monday, July, 15th. The specialty pharmaceutical company reported ($0.49) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.07. The specialty pharmaceutical company had revenue of $2.93 million for the quarter, compared to analyst estimates of $3.64 million. Kalvista Pharmaceuticals had a negative return on equity of 24.57% and a negative net margin of 127.20%. View Kalvista Pharmaceuticals' Earnings History.
When is Kalvista Pharmaceuticals' next earnings date?
What price target have analysts set for KALV?
7 brokers have issued 12-month price objectives for Kalvista Pharmaceuticals' stock. Their predictions range from $30.00 to $35.00. On average, they anticipate Kalvista Pharmaceuticals' stock price to reach $31.50 in the next year. This suggests a possible upside of 88.8% from the stock's current price. View Analyst Price Targets for Kalvista Pharmaceuticals.
What is the consensus analysts' recommendation for Kalvista Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kalvista Pharmaceuticals.
Has Kalvista Pharmaceuticals been receiving favorable news coverage?
News headlines about KALV stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kalvista Pharmaceuticals earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Kalvista Pharmaceuticals.
Who are some of Kalvista Pharmaceuticals' key competitors?
Some companies that are related to Kalvista Pharmaceuticals include ArQule (ARQL), Radius Health (RDUS), Esperion Therapeutics (ESPR), Odonate Therapeutics (ODT), Zymeworks (ZYME), Omeros (OMER), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Dicerna Pharmaceuticals (DRNA), Y-mAbs Therapeutics (YMAB), Cara Therapeutics (CARA), Spectrum Pharmaceuticals (SPPI), Principia Biopharma (PRNB), Emisphere Technologies (EMIS) and Axsome Therapeutics (AXSM).
What other stocks do shareholders of Kalvista Pharmaceuticals own?
Who are Kalvista Pharmaceuticals' key executives?
Kalvista Pharmaceuticals' management team includes the folowing people:
- Mr. Thomas Andrew Crockett, CEO & Director (Age 44)
- Mr. Benjamin L. Palleiko, Chief Bus. Officer & CFO (Age 53)
- Mr. Andreas Maetzel M.D., M.Sc., Ph.D., Sr. VP of Medical (Age 56)
- Mr. John B. McKune, VP of Fin. (Age 43)
- Dr. Edward P. Feener, Chief Scientific Officer (Age 59)
Who are Kalvista Pharmaceuticals' major shareholders?
Kalvista Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include SV Health Investors LLC (9.89%), BlackRock Inc. (4.24%), VHCP Management III LLC (3.67%), Vanguard Group Inc. (3.04%), Pictet Asset Management Ltd. (2.61%) and Pictet Asset Management Ltd. (2.61%). Company insiders that own Kalvista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Holdings A/S Novo, Life Sciences Fund Iv (Gp) Sv, Rajeev M Shah, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View Institutional Ownership Trends for Kalvista Pharmaceuticals.
Which institutional investors are selling Kalvista Pharmaceuticals stock?
KALV stock was sold by a variety of institutional investors in the last quarter, including VHCP Management III LLC, VHCP Management II LLC, SV Health Investors LLC, Invesco Ltd., International Biotechnology Trust PLC, JPMorgan Chase & Co., Susquehanna International Group LLP and First Quadrant L P CA. Company insiders that have sold Kalvista Pharmaceuticals company stock in the last year include Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View Insider Buying and Selling for Kalvista Pharmaceuticals.
Which institutional investors are buying Kalvista Pharmaceuticals stock?
KALV stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Pictet Asset Management Ltd., Pictet Asset Management Ltd., Vanguard Group Inc., Point72 Asset Management L.P., Northern Trust Corp, Bank of New York Mellon Corp and Charles Schwab Investment Management Inc.. Company insiders that have bought Kalvista Pharmaceuticals stock in the last two years include Albert Cha and Rajeev M Shah. View Insider Buying and Selling for Kalvista Pharmaceuticals.
How do I buy shares of Kalvista Pharmaceuticals?
Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kalvista Pharmaceuticals' stock price today?
One share of KALV stock can currently be purchased for approximately $16.68.
How big of a company is Kalvista Pharmaceuticals?
Kalvista Pharmaceuticals has a market capitalization of $290.03 million and generates $16.13 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.View Additional Information About Kalvista Pharmaceuticals.
What is Kalvista Pharmaceuticals' official website?
How can I contact Kalvista Pharmaceuticals?
Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]
MarketBeat Community Rating for Kalvista Pharmaceuticals (NASDAQ KALV)
MarketBeat's community ratings are surveys of what our community members think about Kalvista Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALV will underperform the S&P 500 over the long term. You may vote once every thirty days.
